The firm is an early-stage life sciences focused venture capital investor. The firm targets Series A investment rounds but considers later stage investments and plans to make follow-on commitments throughout a company’s life cycle. Typical initial check sizes can range from $1M to $2.5M. The firm may lead or co-invest on a case-by-case basis and often syndicates with other strong life science investors. The firm invests across the United States, with a focus on underserved or underrepresented regions.
The firm is interested in medical devices, diagnostics, digital health, and medical instruments. The firm does not invest in traditional drug assets but may consider peripheral areas such as drug delivery or platform technologies. For medical devices, the firm primarily considers products with B2B models and a clear FDA regulatory pathway. The firm is opportunistic in terms of indications/disease areas. For development stage, the firm prefers companies with products or assets that are within 18 months of commercialization and have a well-defined regulatory pathway.
There is no specific requirement for companies and the management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment